[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Enliven Therapeutics (ELVN) disclosed insider transactions by its Chief Operating Officer. On 11/07/2025, the reporting person executed sales of 6,054 shares at a weighted average price of $17.3503 and 613 shares at a weighted average price of $17.9371, effected under a Rule 10b5-1 trading plan adopted on September 30, 2024.
The trades were completed in multiple transactions within disclosed price ranges, and the shares are held indirectly by The Patel / Dong Family Trust, for which the reporting person serves as trustee. Following the reported sales, beneficial ownership stood at 269,974 shares held indirectly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 6,667 shares ($116,034)
Net Sell
2 txns
Insider
Patel Anish
Role
CHIEF OPERATING OFFICER
Sold
6,667 shs ($116K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,054 | $17.3503 | $105K |
| Sale | Common Stock | 613 | $17.9371 | $11K |
Holdings After Transaction:
Common Stock — 270,587 shares (Indirect, See footnote)
Footnotes (1)
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). This transaction was executed in multiple trades at prices ranging from $16.825 to $17.8248. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Patel / Dong Family Trust. This transaction was executed in multiple trades at prices ranging from $17.835 to $18.265. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did ELVN report?
The COO reported sales of 6,054 shares at a weighted average of $17.3503 and 613 shares at a weighted average of $17.9371 on 11/07/2025.
Were the ELVN sales under a 10b5-1 plan?
Yes. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024.
What are the price ranges for the ELVN trades?
For 6,054 shares: $16.825–$17.8248. For 613 shares: $17.835–$18.265.
What is the reporting person’s role at ELVN?
The reporting person is the company’s Chief Operating Officer.